Janux Therapeutics (JANX) Operating Expenses (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Operating Expenses data on file, last reported at $37.9 million in Q1 2026.

• On a quarterly basis, Operating Expenses rose 8.74% year-over-year to $37.9 million in Q1 2026; TTM through Mar 2026 was $170.7 million, a 38.88% increase from a year earlier, with the FY2025 full-year figure at $167.7 million, up 53.21% from the prior year.
• Operating Expenses for Q1 2026 stood at $37.9 million, down from $42.4 million in the prior quarter.
• Over the last five years, Operating Expenses for JANX reached as high as $45.3 million in Q3 2025 and fell as low as $15.1 million in Q1 2022.
• Historically, Operating Expenses has averaged $27.8 million across 5 years, with a median of $22.3 million in 2023.
• Across the five-year window, Operating Expenses jumped 467.98% in 2022 and dropped 11.9% in 2023, its largest moves.
• Year by year, Operating Expenses stood at $21.1 million in 2022, then decreased by 11.9% to $18.6 million in 2023, then soared by 56.05% to $29.0 million in 2024, then surged by 46.1% to $42.4 million in 2025, then retreated by 10.51% to $37.9 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $37.9 million in Q1 2026, $42.4 million in Q4 2025, and $45.3 million in Q3 2025.